Next Article in Journal
Bone Marrow Gene Therapy for HIV/AIDS
Previous Article in Journal
Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia
Article Menu

Export Article

Open AccessArticle
Viruses 2015, 7(7), 3891-3909;

Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine

First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Academic Editor: Curt Hagedorn
Received: 22 April 2015 / Revised: 20 June 2015 / Accepted: 1 July 2015 / Published: 17 July 2015
(This article belongs to the Section Antivirals & Vaccines)
Full-Text   |   PDF [1182 KB, uploaded 17 July 2015]   |  


Coxsackievirus A16 (CA16) and enterovirus 71 (EV71), both of which can cause hand, foot and mouth disease (HFMD), are responsible for large epidemics in Asian and Pacific areas. Although inactivated EV71 vaccines have completed testing in phase III clinical trials in Mainland China, CA16 vaccines are still under development. A Vero cell-based inactivated CA16 vaccine was developed by our group. Screening identified a CA16 vaccine strain (CC024) isolated from HFMD patients, which had broad cross-protective abilities and satisfied all requirements for vaccine production. Identification of the biological characteristics showed that the CA16CC024 strain had the highest titer (107.5 CCID50/mL) in Vero cells, which would benefit the development of an EV71/CA16 divalent vaccine. A potential vaccine manufacturing process was established, including the selection of optimal time for virus harvesting, membrane for diafiltration and concentration, gel-filtration chromatography for the down-stream virus purification and virus inactivation method. Altogether, the analyses suggested that the CC-16, a limiting dilution clone of the CC024 strain, with good genetic stability, high titer and broad-spectrum immunogenicity, would be the best candidate strain for a CA16 inactivated vaccine. Therefore, our study provides valuable information for the development of a Vero cell-based CA16 or EV71-CA16 divalent inactivated vaccine. View Full-Text
Keywords: Coxsackievirus A16; HFMD; vaccine candidate strain; inactivated vaccine Coxsackievirus A16; HFMD; vaccine candidate strain; inactivated vaccine

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Li, J.; Liu, G.; Liu, X.; Yang, J.; Chang, J.; Zhang, W.; Yu, X.-F. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine. Viruses 2015, 7, 3891-3909.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top